In " Episode 3 " of the series on " Present and future of diagnostics in prostate cancer ", Assoc. Prof. Paweł Rajwa (PL) and Prof. Scott Eggener (US) engage in a thought-provoking discussion about renaming Gleason 6 (Grade Group 1) prostate cancer. The episode digs into the reasons why many experts believe this change is necessary, and the potential benefits it could bring to clinical practice, particularly in reducing overdiagnosis/overtreatment and improving patient outcomes. Prof. Eggener discusses the argument that Gleason 6 (Grade Group 1) might not behave like typical cancer, as it rarely leads to metastasis or death, and that renaming it could positively guide management decisions, particularly with active surveillance. The conversation touches on the implications of this change on prostate cancer screening and how it could alter the way clinicians approach diagnosis and treatment in the future. For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts , Spotify , EAU YouTube channel .
